Introduction
A rapidly growing aging population is considered a major global health problem that raises socioeconomic concerns and affects public health. 1, 2 Chronic diseases are becoming more prevalent; they require long-term management and are accompanied by major comorbidities, thus increasing the burden of disease. 3, 4 As a result, many countries have established strategies for reducing the incidence of chronic disease and controlling health expenditures. [5] [6] [7] Among them, diabetes is associated with many complications including cardiovascular disease and stroke, which are serious health problems in aging populations. [8] [9] [10] According to the World Health Organization, the global prevalence of diabetes has rapidly risen from 4.7% in 1980-8.5% in 2014, and diabetes has been projected to be the seventh leading cause of death in 2030. 11 Simultaneously, the burden of disease in the elderly population is expected to increase by 96% from 2004 to 2030. 3 These recent projections underscore the need to implement appropriate management strategies for diabetes to control health expenditures.
According to the Organizations for Economic Co-operation and Development, pharmaceutical expenditure as a share of Korean gross national product was 1.3% in 2013; however, the annual growth of pharmaceutical expenditure was faster than that in other countries. 12 Specifically, diabetes drug consumption nearly doubled between 2000 and 2013. Various factors including physicians' beliefs can affect medicine choices, which may be influenced by the growing number of brand name drugs or overutilization. [13] [14] [15] These reasons could underlie the growing diabetes pharmaceutical expenditure. As a result, the government decided to change diabetes medication reimbursement considering the 2011 clinical practice guideline of the Korean Diabetes Association, foreign guideline and clinical results (Supplementary Appendix figure a). 16, 17 This reimbursement restriction was implemented in July 2011 by the Health Insurance Review and Assessment (HIRA). Since then, medication choice has depended on patient clinical condition, and reimbursement is provided considering patient condition. If the prescribed medication does not meet the guideline, it is not reimbursed by the insurer, and patients are responsible for the cost.
According to previous studies, changes in reimbursement affect a physician's drug prescription decisions. [18] [19] [20] However, some studies suggest that this practice does not influence medication utilization 21, 22 because payment strategy can decrease a physician's incentive to prescribe a high margin drug. Furthermore, there have been concerns about reimbursement restrictions specific to particular countries, 23 which could decrease patient quality of care. One Korean study reports that reimbursement restriction based on clinical factors was associated with a decreased prescription rate for hypertension. 24 Other studies found that changes in medication reimbursement were linked to cost reduction and utilization. [25] [26] [27] However, there remains a lack of data in the area of reimbursement restriction for diabetes, specifically changes in prescription patterns and quality of care after the 2011 intervention.
We investigated whether the introduction of the reimbursement criteria under the clinical guideline affected several measures of outpatient prescription patterns and cost. As the introduction of reimbursement criteria could have affected drug choice, we studied whether there was any change in the prescription of oral hypoglycemic agents in single or combination therapy. Furthermore, as it could also influence physicians' choices between brand name and generic drugs, we evaluated changes in brand name prescribing. We also assessed pharmaceutical expenditure after the 2011 introduction of reimbursement criteria for diabetes. Finally, as limited choice could negatively affect patient outcome, we examined hospital admission after reimbursement criteria implementation.
Methods

Database and data collection
We used National Health Insurance Sampling (NHIS) cohort data from 2002 to 2013 to investigate changes in oral hypoglycemic agents after reimbursement restriction introduction. This included personal demographic information, medical treatment data, and hospital characteristics. The baseline population was 1 025 340 participants who were randomly selected, accounting for 2.2% of the total eligible Korean population in 2002. 28 These data were representative of population-based cohort data in Korea. Among them, we selected type 2 diabetes patients using the International Classification of Disease (ICD)-10 codes (E11-E14). We considered the date of diagnosis based on health care utilization including outpatient and inpatient care. The date of diagnosis of diabetes was defined as the first date of visiting health care facilities regardless of facility type. Patients diagnosed with diabetes from 2002-June 2008 were excluded because there was an overall reduction in pharmaceutical costs and a positive list system in 2007, which could affect our outcome variables. We also excluded any patient who was ever prescribed insulin treatment because our focus was on changes in oral hypoglycemic agents. Finally, we excluded patients who were not prescribed diabetes medication and included age groups between 20-79 years olds. Ultimately, 26 315 patients were included in our study.
Variables
The outcome variables were prescription rate (single therapy, combination therapy and brand name drugs), pharmaceutical expenditure, and hospital admission for diabetes. First, we classified oral hypoglycemic agents used in outpatient care into seven categories based on medical codes (ATC code: A10B). Next, we calculated the number of prescribed medications based on seven categories: biguanides, sulfonylureas, combinations of oral blood glucoselowering drugs, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors and other blood glucose-lowering drugs. Second, we classified patients as receiving single or combination therapy based on reimbursement restriction. We defined single therapy as prescription of metformin as an oral hypoglycemic agent and combination therapy as a prescription of two medications covered by the NHI (Supplementary Appendix). Brand name drug status was based on medication data that included information on whether it was newly introduced. If a medication was newly introduced, we defined it as a brand name drug (Supplementary Appendix). Pharmaceutical expenditure included total medication cost per outpatient visit. Hospital admission was measured based on ICD 10 codes (E11-14). If a patient was admitted after an outpatient visit, we classified admission as 'yes.' Finally, all outcome variables were aggregated by month.
The primary variable of interest in this study was the level and overall trend change in outcome variables after introduction of the criteria for diabetes reimbursement. Level change indicates the change at the moment of intervention. Trend change is the rate of change of an outcome variable, defined as an increase or decrease in the slope of the segment after the intervention compared with the segment preceding the intervention (Supplementary Appendix). The index date of introduction of diabetes reimbursement restriction was July 2011. To investigate changes in outcome variables, we used a dummy variable based on the index date; the time before the introduction of reimbursement restriction was defined as 0, and the time after the introduction of reimbursement restriction was defined as 1. In addition, our analysis of trends examined linear changes after reimbursement restriction introduction. The overall trends were stratified by month and included data from July 2008 to December 2013.
We adjusted for patient and hospital characteristics when analyzing changes in outcome variables after the introduction of diabetes reimbursement restriction. Patient characteristics such as sex, age (20-39, 40-59, or 60-79 years), complications (none, single, or multiple), Charlson comorbidity index, insurance type (medical aid, self-employed, or employee), income status (bottom, middle-bottom, middle-top, or top) and year of diagnosis were included in our analysis. Complications were based on specific ICD-10 codes; if the code was .9 (without complications) or 0.7 (multiple complications), we classified the patient as 'none' or 'multiple', respectively. Other patients with specific ICD-10 codes were classified as a 'single' complication. Hospital characteristics included type of hospital (clinic, hospital, or general hospital), hospital location (metropolitan or non-metropolitan), number of beds and number of doctors.
Statistical analysis
To evaluate changes in outcome variables after diabetes reimbursement restriction, we used an interrupted time series study design using generalized estimating equations. [29] [30] [31] [32] We performed Poisson regression analysis with a log link function to evaluate changes in the pattern of prescriptions for single and combination therapies and brand name drugs. A gamma generalized linear model based on the log link function was used to evaluate pharmaceutical expenditure. In addition, subgroup analyses were performed by hospital type. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc.; Cary, NC, USA). P-values <0.05 were considered statistically significant.
Results
The data used in our study were from 26 315 diabetes patients and 9907 medical institutions. Most patients were 20-39 years old (n = 13 073, 49.7%), and the smallest age group was 60-79 years old (n = 2054, 7.8%). Most patients with diabetes had multiple complications (n = 18 831, 71.6%), but 25.7% had no complications. Regarding insurance type, most patients were enrolled as employees, but there was a small proportion of medical aid patients (n = 2,164, 8.2%). Regarding hospital type, clinics were the most common (86.4%) (table 1).
The average prescription rate per month was increasing in both single therapy and brand-name drug after reimbursement restriction introduction. Conversely, decreases were observed in combination therapy. Pharmaceutical expenditure was increased after introduction of the reimbursement restriction; however, these differences were not statistically significant. Hospital admission for diabetes seemed to decrease after the intervention (table 2) .
The interrupted analysis showed that prescription rates per month changed after reimbursement restriction introduction. There were significant changes in prescription rates for single therapy (9.9%) and brand name drugs (-6.2%); however, the directions of the changes were different. In addition, significant trends for lower prescription rates were observed for combination therapy (-1.7%) and brand name drugs (-0.8%) after reimbursement restriction introduction, whereas rates increased for single therapy (0.8%). Regarding pharmaceutical cost per month, both the level (-8.4%) and trend change (-0.3%) decreased. Regarding hospital admission, we did not observe a significant change after reimbursement restriction introduction ( figure 1, Supplementary Appendix tables  a and b) .
Subgroup analyses by type of hospital for level and trend change were performed. Regarding clinics, we found significant decreases in trend changes for prescription rates for combination therapy (-1.5%) and brand name drugs (-0.8%) and pharmaceutical cost (-0.3%). The trend change tended to decrease in the prescription rates of combination therapy (-2.5%) and brand name drugs (-1.3%) in the hospital. Trend changes after reimbursement restriction introduction were observed for both prescription rate (single therapy: 0.9%, combination therapy: -2.0%, brand name drugs: -0.6%) and pharmaceutical cost (-0.7%) in general hospitals (table 3) .
Discussion
Physicians' decisions about prescription can be affected by many factors and can lead to drug choices such as initial drug selection (patients diagnosed with diabetes), subsequent drug selection (patients who continue to use drugs) and choice of habitual drugs such as brand-name drugs. Drug selection can result in better patient outcomes, or vice versa, or affect the cost of drug use. Therefore, this study was to evaluate the effect of reimbursement restrictions on changes in prescription patterns, related pharmaceutical expenditures and patient outcomes.
Our results show that the introduction of reimbursement restriction affected prescription rate in outpatient care. Single therapy significantly increased at the moment of reimbursement restriction introduction, and the overall prescription rate increased compared with the previous trend. Combination therapy prescription rate tended to decrease. Regarding brand name drugs, the prescription rate decreased at the moment of reimbursement restriction introduction, and a similar reduced trend was observed after the intervention. Plausible explanation is related to the physicians' decision to prescribe a given drug. 33 Physicians would have preferred to use relatively expensive brand name drugs or combination therapy that was not clinically necessary before reimbursement restriction introduction. After 2011, prescriptions are based on a clinical guideline; if the drug is not suitable according to the clinical guideline, it is not covered by NHI. Reimbursement restriction based on the clinical guideline will affect physicians' habitual drug choice 34, 35 and offset the marketing effectiveness of the pharmaceutical industry. On the patient side, not only the clinical condition but also the patient's drug burden 36 is taken into consideration, which can affect the choice of drug by physicians. In addition, insurance coverage is directly related to the profit of physicians, and they will not prefer prescription drugs not covered by NHI (Supplementary Appendix  figure b) . As a result, changes in drug decisions have led to reductions in both brand name drug and combination therapy prescriptions, whereas prescription of single therapy has become more common due to the clinical guideline.
Regarding pharmaceutical costs, reimbursement restriction introduction was associated with significant cost reductions and trend change; the monthly growth rate decreased from 0.93% to 0.59%. Although single therapy costs increased, these were offset by reductions in both combination therapy and brand name drugs. Indeed, single therapy with metformin is the cheapest drug of all diabetes medications. However, there is also the possibility of increasing pharmaceutical costs for drugs not covered by NHI. As mentioned above, inappropriate combination therapy is not covered by NHI and patients are required to pay for this therapy. Fees for medication not covered by NHI were not included in our data, therefore we could not measure this expenditure. However, costs not covered by NHI are not expected to be large. In 2006, the average proportion of uninsured fees in outpatient care was approximately 8.9%, and the list of uninsured medication partially expanded with reimbursement restriction introduction. 37 Because uninsured medication was included under NHI, the proportion of uninsured costs among total costs decreased after the intervention. In addition, cost containment policy can affect the trends change in pharmaceutical expenditure. Since April 2012, a cost containment policy for drug has been implemented that could potentially affect our findings. However, the monthly average drug cost has decreased immediately after introduction of the reimbursement restriction, and no sharp change in drug costs has been observed since 2012. Therefore, our findings show that reimbursement restrictions have a positive impact on reducing the growth of pharmaceutical expenditures. Finally, we explored patient outcomes to evaluate whether these changes had positive or negative effects on patient care. Opponents argue that it may induce to decrease in quality of care due to limited scope of medication. We did not find a significant decrease in hospital admission after intervention, suggesting that the quality of care was not affected by reimbursement restriction introduction. However, further studies considering detailed indicators, including clinical factors, are needed to more accurately evaluate quality of care after the intervention.
The introduction of clinical guidelines for reimbursement restriction is considered a powerful method for controlling drug utilization by diabetes patients, and it could affect patient care and health expenditure. One positive effect would be associated with changing physicians' decisions for diabetes prescriptions. Specifically, guidelines could reduce over-utilization or the prescription of clinically unnecessary medicine. In addition, guidelines could reduce pharmaceutical costs. Conversely, limiting drug choice could negatively affect patient outcomes. We found no evidence of a change in quality of care following guideline implementation. However, different effects on patient care are possible when considering other clinical factors. Thus, quality of care must be carefully considered, especially when changes are made to clinical guidelines. Our findings demonstrate that reimbursement restrictions contributed to a reduction in inappropriate drug utilization and lower health expenditures.
Our study has several strengths. To the best of our knowledge, it is the first to evaluate the effect of diabetes reimbursement restriction on drug utilization and patient outcome in Korea. Previous investigations considered drug utilization, but no prior study evaluated patient outcome. Second, the interrupted time series analysis design is a powerful method for evaluating political change. Our results provide valuable evidence to policy makers regarding the effects of reimbursement system changes, and similar studies could be performed for other diseases. Third, we used NHI cohort data including a large, representative sample of individuals in Korea; therefore, our results should be of significance to policy makers. Finally, our results are also meaningful to other countries that are considering introducing reimbursement restriction to reduce health expenditures.
Despite these strengths, our study does have some limitations. First, we used claims data, so we were unable to consider patient clinical conditions that affect diabetes prescription changes. Prescription rates could be impacted by changes in clinical condition. However, the reimbursement restriction are based on patient clinical condition, which was reflected in the medical codes. Second, pharmaceutical costs are influenced by other political changes such as those aimed at cost reduction of medications. In addition, the cost values did not include uninsured pharmaceutical costs, which could be substantial. Third, we could not consider other clinical indicators of patient quality of care. As patient admission was the sole quality indicator, further studies considering multiple indices are needed to evaluate quality of care. Finally, we only evaluated changes in oral prescriptions; the results may be different for other drugs including insulin. 
Conclusion
In conclusion, our results provide evidence to policymakers that reimbursement restriction affects physician prescription patterns and pharmaceutical costs. We found no changes in quality of care for diabetes patients after the intervention. However, continuously revised reimbursement restriction reflecting evidence-based clinical guidelines are needed to maintain quality of care. Thus, policy makers should only implement suitable reimbursement restrictions after considering clinical evidence to improve effective diabetes medication prescription and control pharmaceutical expenditure.
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Key points
Changes in prescription patterns and quality of care after the introduction of reimbursement restriction in diabetes patients are uncertain. Restrictions on reimbursement have reduced the pharmaceutical expenditure by influencing physicians' prescriptions, but do not adversely affect patient outcomes. Our findings provide evidence to policy makers that reimbursement restrictions can potentially reduce drug overuse and are an effective way to control the growth of pharmaceutical expenditures. 
